Recombinant hemagglutinin influenza vaccine provides broader spectrum protection

References

• Milián E, Kamen AA. Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int. 2015;2015:1–11.
   Web of Science ®Google Scholar
• Cox MMJ, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J Invert Pathol. 2011;107:S31–S41.
   PubMed Web of Science ®Google Scholar
• Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol. 2005;23:567–575.
   PubMed Web of Science ®Google Scholar
• Wang K, Holtz KM, Anderson K, et al. Expression and purification of an influenza hemagglutinin – one step closer to a recombinant protein-based influenza vaccine. Vaccine. 2006;24:2176–2185.
   PubMed Web of Science ®Google Scholar
• Dunkle LM, Izikson R, Patriarca PA, et al. Clinical efficacy of quadrivalent recombinant influenza (Flu) vaccine vs. quadrivalent inactivated influenza vaccine (IIV) in adults 50 years of age and older – abstract I-299a. Abstracts: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2015 Sept 17–22; San Diego, CA; Washington (DC): American Society of Microbiology.
   Google Scholar
• Cox MMJ, Dunkle LM, Goldenthal K, et al. Efficacy of recombinant influenza vaccine (Flublok Quadrivalent, RIVr) versus egg-derived inactivated vaccine4 (IIV4) in adults 50 years of age and older during a season characterized by antigenic mismatch between circulating and vaccine H3N2 strains. 19th Annual Conference on Vaccine Research – Abstract S4; 2016 Apr 18–20; Baltimore, ML; Bethesda (MD): National Foundation for Infectious Diseases.
   Google Scholar
• Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012–2013 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLos One. 2014;9(3):e92153.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, El Sahly HM, King J, et al. Protective efficacy of a trivalent recombinant heagglutinin protein vaccine (FluBlok) against culture-confirmed influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011;29:7733–7739.
   PubMed Web of Science ®Google Scholar
• Cox MMJ, Anderson DK. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influen Other Resp Viruses. 2007;1:35–40.
   PubMed Web of Science ®Google Scholar
• Janjua NZ, Skowronski DM, De Serres G, et al. Estimates of influenza vaccine effectiveness for 2007–2008 from Canada’s Sentinel Surveillance System: cross-protection against major and minor variants. J Infect Dis. 2012;205:1858–1868.
   PubMed Web of Science ®Google Scholar
• Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine. 2011;29:2272–2278.
   PubMed Web of Science ®Google Scholar
• Keitel WA, Treanor JJ, El Sahly HM, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIV) among persons ≥65 years old. Vaccine. 2010;28:379–385.
   Web of Science ®Google Scholar
• Safdar A, Rodriguez MA, Fayad LE, et al. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin’s B-cell lymphoma. J Infect Dis. 2006;194:1394–1397.
   PubMed Web of Science ®Google Scholar
• Powers DC, Smith GE, Anderson EL, et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well-tolerated and induce protective immune responses in healthy adults. J Infect Dis. 1995;171:1595–1599.
   PubMed Web of Science ®Google Scholar
• Appiah GD, Blanton L, D’Mello T, et al. Influenza activity – United States, 2014–15 season and composition of the 2015–16 influenza vaccine. Morbid Mortal Wkly Rep. 2015;64:583–590.
   PubMed Web of Science ®Google Scholar
• Flannery B, Clippard J. End-of-season influenza vaccine effectiveness estimates for the 2014–15 season: US Influenza Vaccine Effectiveness (Flu VE) Network. Advisory Committee on Immunization Practices [Online]; 2015 Jun 24 [cited 2015 Sep 8]. Available from: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-06/flu-02-flannery.pdf.
   Google Scholar
• Fineberg H. Pandemic preparedness and response – lessons from the H1N1 influenza of 2009. N Engl J Med. 2014;370:1335–1342.
   PubMed Web of Science ®Google Scholar
• Shrestha S, Swerdlow D, Borse R, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis. 2011;52:S75–S82.
   PubMed Web of Science ®Google Scholar
• President’s Council of Advisors on Science and Technology. Report to the President on U.S. Preparations for 2009-H1N1 influenza pandemic. Washington, DC: s.n.; 2009.
   Google Scholar
• WHO. Pandemic influenza vaccine manufacturing process and timeline. World Health Organization [Online]; 2016 [cited 2016 Mar 28] Available from: http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090806/en/.
   Google Scholar
• Wagner R, Geyer H, Geyer R, et al. N-acetyl-B-glucosaminidase accounts for differences in glycosylation of influenza virus nemagglutinin expressed in insect cells from a baculovirus vector. J Virol. 1996;70:4103–4109.
   PubMed Web of Science ®Google Scholar
• Chen J-R, Yu Y-H, Tseng Y-C, et al. Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. Proc Natl Acad Sci USA. 2014;111:2476–2481.
   PubMed Web of Science ®Google Scholar
• Holtz KM, Anderson DK, Cox MM. Production of a recombinant influenza vaccine using the baculovirus expression vector system. BioProcess J. 2003;2:65–73.
   Google Scholar
• Yoden S, Kida H, Kuwabara M, et al. Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. Virus Res. 1986;4:251–264.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. J Amer Med Assoc. 2007;297:1577–1582.
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Shay DJ, Shimabukuro TT, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices – United States, 2013–2014. Morbid Mortal Wk Rep. 2013;62:1–43.
   PubMedGoogle Scholar
• Izikson R, Laffell D, Bock A, et al. Comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age. Vaccine. 2015;33:6622–6628.
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–645.
   PubMed Web of Science ®Google Scholar
• Sanofi-Pasteur. Fluzone influlenza vaccine. Prescribing Information [Online]; 2015 Jun 19 [cited 2016 Jan 12]. Available from: http://www.fluzone.com/health-care-professionals/index.cfm.
   Google Scholar
• Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig. 1998;15:1–12.
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole cell pertussis vaccine. N Engl J Med. 1996;334:340–355.
   Web of Science ®Google Scholar
• Rosenthal S, Chen R, Hadler S. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine: a post-marketing assessment. Arch Pediatr Adolesc Med. 1996;150:457–460.
   PubMedGoogle Scholar
• Johansson BE, Cox MMJ. Influenza viral neuraminidase: the forgotten antigen. Expert Rev Vaccines. 2011;10:1683–1695.
   PubMed Web of Science ®Google Scholar
• Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013;3:521–530.
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Choi A, Izikson R, et al. Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans. MBio. 2015;6:e01996–e02015.
   Google Scholar
• Schulze I. Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J Infect Dis. 1997;176:S24–S28.
   PubMedGoogle Scholar
• Wang CC, Chen J-R, Tseng Y-C, et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci USA. 2009;106:18137–18142.
   PubMed Web of Science ®Google Scholar
• Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol. 1968;2:778–786.
   PubMed Web of Science ®Google Scholar